Journal
JOURNAL OF IMMUNOLOGY
Volume 186, Issue 6, Pages 3770-3778Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1003082
Keywords
-
Categories
Funding
- German Research Organization (Deutsche Forschungsgemeinschaft) [De 1478/1-1, Va 124/7-1]
- Wilhelm Sander Foundation
Ask authors/readers for more resources
Dimeric IgA Abs contribute significantly to the humoral part of the mucosal immune system. However, their potential as immunotherapeutic agent has hardly been explored. In this article, we describe the production, purification, and functional evaluation of recombinant dimeric IgA against the epidermal growth factor receptor. Human joining chain-containing IgA was produced by non-adherent Chinese hamster ovarian (CHO)-K1 cells under serum-free conditions. Purification by anti-human kappa and anti-His-tag affinity, as well as size exclusion chromatography, resulted in a homogenous preparation of highly pure IgA dimers. Functional studies demonstrated dimeric IgA to be at least as effective as monomeric IgA in triggering Ab-dependent cellular cytotoxicity by isolated monocytes or polymorphonuclear cell and in human whole-blood assays. Importantly, dimeric IgA was more effective in F(ab)-mediated killing mechanisms, such as inhibition of ligand binding, receptor down modulation, and growth inhibition. Furthermore, only dimeric but not monomeric IgA or IgG was directionally transported by the polymeric Ig receptor through an epithelial cell monolayer. Together, these studies demonstrate that recombinant dimeric IgA Abs recruit a distinct repertoire of effector functions compared with monomeric IgA or IgG1 Abs. The Journal of Immunology, 2011, 186: 3770-3778.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available